Medpace Holdings Inc ( (MEDP) ) has released its Q3 earnings. Here is a breakdown of the information Medpace Holdings Inc presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Medpace Holdings Inc. is a global, full-service clinical contract research organization (CRO) that provides Phase I-IV clinical development services to the biotechnology, pharmaceutical, and medical device industries. Headquartered in Cincinnati, Ohio, Medpace is known for its scientifically-driven approach to accelerating the development of medical therapeutics.
In its third-quarter 2025 earnings report, Medpace Holdings Inc. announced a significant increase in revenue and net new business awards, showcasing a strong financial performance. The company’s revenue for the quarter reached $659.9 million, marking a 23.7% increase from the previous year, while net new business awards surged by 47.9% to $789.6 million.
Key financial metrics from the report include a GAAP net income of $111.1 million, or $3.86 per diluted share, representing an improvement from the previous year’s figures. The company’s EBITDA also saw a notable increase of 24.9% to $148.4 million, with an EBITDA margin of 22.5%. These results highlight Medpace’s robust financial health and operational efficiency.
Looking ahead, Medpace has provided a positive financial outlook for the full year 2025, forecasting revenue growth between 17.6% and 20.0% over 2024. The company anticipates GAAP net income to range between $431.0 million and $439.0 million, with EBITDA expected to be between $545.0 million and $555.0 million.
Overall, Medpace Holdings Inc. continues to demonstrate strong growth and financial stability, positioning itself well for future success in the clinical research industry.